What is the market price of each box of Talazoparib?

Talazoparib is a polyADPribose polymerase (PARP) inhibitor, mainly used to treat advanced breast cancer related to BRCA mutations. As a new type of targeted drug, it shows good efficacy in inhibiting tumor DNA repair mechanism. Currently, the drug has been approved for marketing in China, and patients can go to qualified hospital pharmacies for consultation and purchase. However, the specific selling price varies depending on the region, hospital policies and medical insurance coverage.

In overseas markets, the original drug of talazoparib is circulated in multiple versions. The prices of the original drugs in Hong Kong and Europe are generally on the high side. Among them, the latest market price of 0.25 mg 30 tablets is between RMB 10,000 and RMB 20,000; while the price of 1 mg 30 tablets packaged in higher specifications reaches more than RMB 50,000 per box. This high cost often becomes a financial burden for patients to continue treatment, so many patients will consider other ways to obtain drugs with the same ingredients.

In order to meet the financial affordability of more patients, some countries also provide generic versions of talazoparib. For example, the current market price of the generic version 1mg*30 tablets produced in Laos is about 4,000 yuan, which is significantly lower than the price of the original drug, making it the choice of some patients with greater financial pressure. Although it is a generic drug, its ingredients are consistent with the original drug. It is still recommended to evaluate the efficacy and risks under the guidance of a doctor before use.

To sum up, talazoparib is already on the market in China, and the purchasing channels are relatively formal, but the price may be higher. There is a large price gap between the Hong Kong version and the European version of the original drug in overseas markets, ranging from 10,000 to 20,000 yuan to more than 50,000 yuan; while the Laotian generic version provides a more cost-effective option. It is recommended that patients choose a suitable version based on their own condition, financial situation and doctor's advice, and do not buy medicines on their own or blindly change treatment plans.

Reference materials:https://www.talzenna.com/